Eli Lilly And Co Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has seven approved drugs.
There are eighteen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.
There are three hundred and forty-nine patent family members on ELI LILLY AND CO drugs in fifty-five countries and forty-four supplementary protection certificates in eighteen countries.
Summary for Eli Lilly And Co
International Patents: | 349 |
US Patents: | 18 |
Tradenames: | 10 |
Ingredients: | 6 |
NDAs: | 7 |
Drug Master File Entries: | 37 |
Patent Litigation for Eli Lilly And Co: | See patent lawsuits for Eli Lilly And Co |
PTAB Cases with Eli Lilly And Co as petitioner: | See PTAB cases with Eli Lilly And Co as petitioner |
PTAB Cases with Eli Lilly And Co as patent owner: | See PTAB cases with Eli Lilly And Co as patent owner |
Drugs and US Patents for Eli Lilly And Co
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | 11,357,820 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-005 | May 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-001 | May 13, 2022 | RX | Yes | Yes | 9,474,780 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-009 | Mar 28, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-011 | Jul 28, 2023 | RX | Yes | Yes | 11,357,820 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | ZEPBOUND (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-005 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-011 | Mar 28, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eli Lilly And Co
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for Eli Lilly And Co Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
New Zealand | 748274 | ⤷ Try a Trial |
Dominican Republic | P2010000270 | ⤷ Try a Trial |
Hungary | S1700031 | ⤷ Try a Trial |
Croatia | P20040883 | ⤷ Try a Trial |
Japan | 2020500936 | ⤷ Try a Trial |
Cyprus | 1124540 | ⤷ Try a Trial |
Lithuania | 3551617 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eli Lilly And Co Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2288610 | 2017/032 | Ireland | ⤷ Try a Trial | PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
2379528 | 2019/015 | Ireland | ⤷ Try a Trial | PRODUCT NAME: ABEMACICLIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
2379528 | C201930017 | Spain | ⤷ Try a Trial | PRODUCT NAME: ABEMACICLIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1307; DATE OF AUTHORISATION: 20180927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1307; DATE OF FIRST AUTHORISATION IN EEA: 20180927 |
2288610 | LUC00027 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
2379528 | 300969 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ABEMACICLIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1307 20181001 |
2379528 | C02379528/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ABEMACICLIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66833 21.05.2019 |
2379528 | 2019C/507 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.